Purespring Therapeutics Purespring Therapeutics is the first company directly targeting podocytes through AAV gene therapy for kidney disease treatment. Launched in 2020 with substantial funding, the company builds on world-leading kidney disease research from the University of Bristol.
| Ownership Private Company |
Revolutionary AAV gene therapy approach for untreatable kidney diseases
Kidney disease patients, nephrology specialists, biotech investors
Get qualified leads in 10 minutes. Research prospects, find decision makers, and monitor for the perfect moment to reach out.
Last verified: February 2, 2026
Connect with Purespring Therapeutics